GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Lamivudine and lamivudine/zidovudine

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

NIH pediatric ARV guidance - renal and fixed-combination cautions

Product / population
Pediatric-source safety and formulation guidance; no pediatric numeric renal regimen imported
Renal measure
CrCl mL/min as specified in pediatric source

Dosing / renal protocol and limits

Pediatric ARV guidance: lamivudine needs renal adjustment. Do not use lamivudine-containing fixed-dose tablets when CrCl <30 mL/min or on dialysis because individual component doses cannot be adjusted. With sustained CrCl 30-49, the guidance highlights increased exposure and monitoring for hematologic toxicity, potentially requiring a change from the combination.

This is a pediatric-source caution, not a numeric pediatric renal schedule. Adult dose tables elsewhere on this page must not be substituted. Epivir-HBV products have lower concentrations/strengths and are not interchangeable with HIV doses.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/lamivudine

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

NIH adult ARV table - lamivudine label and alternative doses

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl mL/min; HIV lamivudine, not HBV doses or combinations
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Southern African HIV Clinicians Society - lamivudine renal protocol

Adults with HIV; non-U.S. society protocol for single-agent lamivudine

Renal method: Indexed eGFR mL/min/1.73 m2 (CKD-EPI preference stated)
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

NIH pediatric ARV guidance - renal and fixed-combination cautions

Pediatric-source safety and formulation guidance; no pediatric numeric renal regimen imported

Renal method: CrCl mL/min as specified in pediatric source
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNIH adult ARV table - lamivudine label and alternative dosesSouthern African HIV Clinicians Society - lamivudine renal protocolNIH pediatric ARV guidance - renal and fixed-combination cautions
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

HIV and hepatitis-B lamivudine dosing differ. The single-agent and fixed-combination records must not be interchanged.

The preserved source page includes lamivudine and a zidovudine combination. Newly added adult single-agent and pediatric guidance are explicitly scoped; do not transfer single-agent dose changes to the fixed combination. NIH and the Southern African society use different renal approaches and alternatives.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/lamivudine-lamivudineazt/

Usual Dosing (Adults)

HIV: lamivudine 150 mg orally every 12 hours or 300 mg daily. Hepatitis B (Epivir-HBV): 100 mg daily. Combivir contains lamivudine 150 mg plus zidovudine 300 mg: one tablet twice daily.

GRPH-lamivudine-lamivudineazt-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing - Lamivudine for HIV

CrCl (mL/min)Regimen
>50No changes
30 to 49150 mg daily
15 to 29150 mg once, then 100 mg daily
5 to 14150 mg once, then 50 mg daily
<550 mg once, then 25 mg daily
GRPH-lamivudine-lamivudineazt-02 · Source section: Renal Dosing - Lamivudine for HIVRenal section finder

Renal Dosing - Lamivudine for Hepatitis B

CrCl (mL/min)Regimen
>50No changes
30 to 49100 mg once, then 50 mg daily
15 to 29100 mg once, then 25 mg daily
5 to 1435 mg once, then 15 mg daily
<535 mg once, then 10 mg daily
GRPH-lamivudine-lamivudineazt-03 · Source section: Renal Dosing - Lamivudine for Hepatitis BRenal section finder

Renal Dosing - Combivir

CrCl >50 mL/min: no changes. CrCl <50: give each component separately and follow the respective renal dosing recommendations.

GRPH-lamivudine-lamivudineazt-04 · Source section: Renal Dosing - CombivirRenal section finder

Hemodialysis

Lamivudine for HIV: 50 mg once, then 25 to 50 mg daily. For hepatitis B: 35 mg once, then 10 mg daily. Combivir: give components separately, adjusting each by its renal protocol.

GRPH-lamivudine-lamivudineazt-05 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

NIH adult ARV table - lamivudine label and alternative doses

Open original reference

Open / share this exact local source

NIH ClinicalInfo adult ARV panel · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl mL/min; HIV lamivudine, not HBV doses or combinations
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

HIV single-agent lamivudine: usual 300 mg daily or 150 mg twice daily. CrCl 15-29: 150 mg once then 100 mg daily; 5-14: 150 mg once then 50 mg daily; <5/HD: 50 mg once then 25 mg daily. NIH also lists 100-150 mg daily alternatives at these low clearances with limited evidence. Its 30-49 no-adjustment approach incorporates combination-label guidance, unlike the single-agent Epivir label. Do not transfer to lamivudine/zidovudine.

RDM30-100-lamivudine-lamivudineazt-1 · Source locator: NIH adult ARV table - lamivudine label and alternative doses; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-05
Renal-function method
CrCl mL/min; HIV lamivudine, not HBV doses or combinations
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
0a8ad8e97dd4a85bcf99b869045c358e78a5c10ef7a9de023ded6c48a2bb196b
Professional

Southern African HIV Clinicians Society - lamivudine renal protocol

Open original reference

Open / share this exact local source

Southern African HIV Clinicians Society · Adults with HIV; non-U.S. society protocol for single-agent lamivudine

Renal method: Indexed eGFR mL/min/1.73 m2 (CKD-EPI preference stated)
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Single-agent lamivudine, in the society's CKD table: indexed eGFR 30-50 mL/min/1.73 m2, unchanged; 15-30, 150 mg daily; <15, 50 mg daily. HD or PD: first 50 mg, then 25 mg daily; give ART after HD. The adjacent bands overlap at 30; confirm the intended boundary locally.

This non-U.S. professional protocol uses indexed eGFR and differs from the NIH label-dose options at some low-clearance bands. Lamivudine is a U.S.-labeled ingredient, but this is not U.S. FDA dosing. It does not apply to fixed-dose lamivudine/zidovudine.

RDM30-103-lamivudine-lamivudineazt-1 · Source locator: Southern African HIV Clinicians Society - lamivudine renal protocol; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.sahivsoc.org/Guidelines/Module21
Retrieved
2026-09-05
Renal-function method
Indexed eGFR mL/min/1.73 m2 (CKD-EPI preference stated)
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
9d3b07e3c2827b16ad323a665baa0fd13fbf8468f59f9d5fff4396d6afe1183d
Professional

NIH pediatric ARV guidance - renal and fixed-combination cautions

Open original reference

Open / share this exact local source

NIH ClinicalInfo pediatric ARV panel · Pediatric-source safety and formulation guidance; no pediatric numeric renal regimen imported

Renal method: CrCl mL/min as specified in pediatric source
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Pediatric ARV guidance: lamivudine needs renal adjustment. Do not use lamivudine-containing fixed-dose tablets when CrCl <30 mL/min or on dialysis because individual component doses cannot be adjusted. With sustained CrCl 30-49, the guidance highlights increased exposure and monitoring for hematologic toxicity, potentially requiring a change from the combination.

This is a pediatric-source caution, not a numeric pediatric renal schedule. Adult dose tables elsewhere on this page must not be substituted. Epivir-HBV products have lower concentrations/strengths and are not interchangeable with HIV doses.

RDM30-110-lamivudine-lamivudineazt-1 · Source locator: NIH pediatric ARV guidance - renal and fixed-combination cautions; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/lamivudine
Retrieved
2026-09-05
Renal-function method
CrCl mL/min as specified in pediatric source
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
5237aba86fbc68ed8e39d8799abd019e1c595e0a6798aff54ac499034d2ecbe5

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 3 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/lamivudine-lamivudineazt/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
290b7d8f6fe5b4acfd2bc2ce1981a3b9af7aeab3129e396dbdd7a846b8e37c53
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report